EGM
ADCT icon

Engineers Gate Manager’s ADC Therapeutics ADCT Stock Holding History

Engineers Gate Manager’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4K Buy
+13,493
New +$39.4K ﹤0.01% 2181
2026
Q1 		– Sell
-12,071
Closed -$42.6K – 2147
2025
Q4 		$42.6K Buy
+12,071
New +$49K ﹤0.01% 1990

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Engineers Gate Manager's ADCT Position: Q2 2026 in Review

Engineers Gate Manager opened a new position in ADC Therapeutics (ADCT) in Q2 2026: 13,493 shares worth $14.4K. The stake represents ﹤0.01% of the portfolio and ranks #2181 among its holdings. This is a return to the name: Engineers Gate Manager previously reported a position in ADCT as recently as Q4 2025.

Engineers Gate Manager first reported a position in ADCT in Q4 2025 and has held it in 2 quarters since. The position peaked at $42.6K in Q4 2025. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Engineers Gate Manager held 13,493 shares of ADC Therapeutics worth $14.4K as of Q2 2026.
  • ADC Therapeutics was a new Engineers Gate Manager position in Q2 2026.
  • ADC Therapeutics made up ﹤0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #2181 holding.
  • Engineers Gate Manager first reported a position in ADC Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Engineers Gate Manager's ADC Therapeutics position peaked at $42.6K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.